Online inquiry

IVTScrip™ mRNA-Anti-VEGFA, ESBA-1008(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ6958MR)

This product GTTS-WQ6958MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets VEGFA gene. The antibody can be applied in Age-related macular degeneration (AMD) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001025366.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7422
UniProt ID P15692
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-VEGFA, ESBA-1008(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ6958MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ9969MR IVTScrip™ mRNA-Anti-hly, KBSA301(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA KBSA301
GTTS-WQ12129MR IVTScrip™ mRNA-Anti-FOLR1, MORAb-003(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA MORAb-003
GTTS-WQ5353MR IVTScrip™ mRNA-Anti-CD38, CD38-Attenukine(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA CD38-Attenukine
GTTS-WQ7610MR IVTScrip™ mRNA-Anti-CSF3R, G-CSF-Fc-PEG(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA G-CSF-Fc-PEG
GTTS-WQ1204MR IVTScrip™ mRNA-Anti-ERBB2, ABP 980(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA ABP 980
GTTS-WQ10495MR IVTScrip™ mRNA-Anti-CGRP, LY-2951742(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA LY-2951742
GTTS-WQ116MR IVTScrip™ mRNA-Anti-EGFR, 11F8(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA 11F8
GTTS-WQ10692MR IVTScrip™ mRNA-Anti-ALB&IL17A, M-1095(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA M-1095
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW